Meropenem Penetration Across BBB in Patients With CNS Infection and Optimization of Meropenem Treatment

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A prospective, open-label study investigated the pharmacokinetic profile of meropenem in patients with post-neurosurgical central nervous system (CNS) infection, especially its BBB penetration into cerebrospinal fluid (CSF).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Huashan Hospital
• Treatments: Meropenem; Thienamycins

Criteria

Inclusion Criteria:

• at least 18 years of age

• requiring continuous drainage of CSF or gram-negative bacteria were identified from CSF culture

• have temperature fever (T > 37.5℃)

• have signs of meningeal irritation

• white blood cells in CSF > 300 × 10^6/L

Exclusion Criteria:

• hypersensitive to meropenem

• did not receive at least 3 days of meropenem treatment

• are receiving hemodialysis

• unstable vital signs

• have lumbar puncture contraindications and so inappropriate for sample collection

• severe hepatic or renal dysfunction

• status epilepticus

• potential neurodegenerative diseases

• pregnancy

• breast-feeding